Capital Analysts LLC
RCKT icon

Capital Analysts LLC’s Rocket Pharmaceuticals RCKT Stock Holding History

Capital Analysts LLC’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-175
Closed -$3K – 1362
2024
Q3 		$3K Buy
+175
New +$3.58K ﹤0.01% 1187

Other funds holding RCKT

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Analysts LLC's RCKT Position: Q4 2024 in Review

Capital Analysts LLC sold out of Rocket Pharmaceuticals (RCKT) in Q4 2024, closing a stake of 175 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in RCKT in Q3 2024 and held it in 1 quarter. The position peaked at $3K in Q3 2024. 225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

  • Capital Analysts LLC reported no remaining Rocket Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Analysts LLC sold 175 Rocket Pharmaceuticals shares in Q4 2024, an estimated $3K.
  • Capital Analysts LLC first reported a position in Rocket Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Analysts LLC's Rocket Pharmaceuticals position peaked at $3K in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Capital Analysts LLC's 13F filing for Q4 2024, filed 14 Feb 2025.